RxSight (RXST)
(Delayed Data from NSDQ)
$60.21 USD
+1.42 (2.42%)
Updated May 14, 2024 04:00 PM ET
After-Market: $60.26 +0.05 (0.08%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RXST 60.21 +1.42(2.42%)
Will RXST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RXST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXST
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
RXST: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
Other News for RXST
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
What's Driving Establishment Labs Holdings Inc's Surprising 34% Stock Rally?
J.P. Morgan Sticks to Its Buy Rating for RxSight (RXST)
RxSight price raises equity at $56 per share
RxSight, Inc. Announces Pricing of Public Offering of Common Stock